1. Homepage
  2. Equities
  3. Germany
  4. HANSEATISCHE WERTPAPIERBOERSE HAMBURG
  5. Sangui Biotech International, Inc.
  6. News
  7. Summary
    SBH   US80105B1017

SANGUI BIOTECH INTERNATIONAL, INC.

(SBH)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Sangui BioTech International Inc.: - Significant increase in sales in the first nine months - Reduction of operating loss

05/10/2021 | 06:21am EDT

DGAP-News: Sangui BioTech International Inc. / Key word(s): 9 Month figures
Sangui BioTech International Inc.: - Significant increase in sales in the first nine months - Reduction of operating loss

10.05.2021 / 12:19
The issuer is solely responsible for the content of this announcement.



 

Sangui BioTech:

- Significant increase in sales in the first nine months

- Reduction of operating loss

 


Hamburg, May, 10 2021: In the first nine month of fiscal year 2021 (to 30/06/2021) Sangui BioTech International Inc. achieved revenues from royalty income of USD 51,754. In the same period of the previous year the comparable revenue amounted to USD 21,176. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first nine month of the year was above the level of the same period of the previous year.

Operating expenses increased USD 11,731 or 8% to USD 162,793 during the first three quarters. As a result of the above factors, the nine month operating loss decreased USD 18,847 to USD 111,039. Due to the lower exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate loss from the valuation of loans denominated in EURO, the loss of the nine month period increased by USD 24,513 to USD 151,923.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.



10.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1194544  10.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1194544&application_name=news&site_id=zonebourse_sftp

© EQS 2021
All news about SANGUI BIOTECH INTERNATIONAL, INC.
02:38aSANGUI BIOTECH INTERNATIONAL INC. : - Increase in sales in the first nine months of the ye..
EQ
05/16SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Con..
AQ
02/16SANGUI BIOTECH INTERNATIONAL INC. : Significant increase in sales in the first half of the..
EQ
02/11SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Con..
AQ
02/11Sangui Biotech International, Inc. Reports Earnings Results for the Second Quarter and ..
CI
2021SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 18,560 in first quarter - Reduction of ..
EQ
2021SANGUI BIOTECH INTERNATIONAL INC Management's Discussion and Analysis of Financial Con..
AQ
2021Sangui Biotech International, Inc. Reports Earnings Results for the First Quarter Ended..
CI
2021SANGUI BIOTECH INTERNATIONAL INC. : Granulox is awarded the prestigious Prix Galien
EQ
2021SANGUI BIOTECH INTERNATIONAL INC. : - Sales of USD 65,582 in fiscal year 2021 - Reduction ..
EQ
More news
Financials (USD)
Sales 2021 0,07 M - -
Net income 2021 -0,20 M - -
Net Debt 2021 0,79 M - -
P/E ratio 2021 -21,6x
Yield 2021 -
Capitalization 3,09 M 2,87 M -
EV / Sales 2020 134x
EV / Sales 2021 90,6x
Nbr of Employees -
Free-Float 77,7%
Chart SANGUI BIOTECH INTERNATIONAL, INC.
Duration : Period :
Sangui Biotech International, Inc. Technical Analysis Chart | SBH | US80105B1017 | MarketScreener
Income Statement Evolution
Managers and Directors
Thomas Striepe President, CEO, CFO & Director
Hubertus Schmelz Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SANGUI BIOTECH INTERNATIONAL, INC.-7.14%3
MODERNA, INC.-43.98%54 199
LONZA GROUP AG-28.13%40 453
IQVIA HOLDINGS INC.-26.74%39 077
SEAGEN INC.-5.21%26 238
ICON PUBLIC LIMITED COMPANY-32.47%17 114